Aft Forsyth & Company Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 14.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,318 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. Aft Forsyth & Company Inc.’s holdings in Pfizer were worth $402,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. New England Investment & Retirement Group Inc. purchased a new stake in shares of Pfizer in the first quarter valued at about $26,000. Lion Street Advisors LLC purchased a new position in Pfizer during the first quarter worth about $27,000. TFO TDC LLC purchased a new position in Pfizer during the fourth quarter worth about $37,000. Benjamin Edwards Inc. boosted its stake in Pfizer by 49.8% during the first quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 335 shares during the period. Finally, Wealthcare Capital Management LLC boosted its stake in Pfizer by 61.2% during the fourth quarter. Wealthcare Capital Management LLC now owns 1,069 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 406 shares during the period. 69.91% of the stock is owned by hedge funds and other institutional investors.

NYSE:PFE traded up $0.24 during mid-day trading on Friday, hitting $37.50. The stock had a trading volume of 14,885,114 shares, compared to its average volume of 22,354,300. The stock has a 50-day simple moving average of $36.51 and a two-hundred day simple moving average of $36.84. The company has a market capitalization of $206.97 billion, a PE ratio of 13.39, a PEG ratio of 2.72 and a beta of 0.71. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $44.56. The company has a current ratio of 1.02, a quick ratio of 0.78 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.09. The firm had revenue of $12.03 billion for the quarter, compared to analysts’ expectations of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. The firm’s revenue was down 8.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.85 earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.81 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.38 per share. The ex-dividend date is Thursday, May 7th. This represents a $1.52 dividend on an annualized basis and a yield of 4.05%. Pfizer’s payout ratio is currently 51.53%.

In related news, major shareholder Pfizer Inc acquired 312,500 shares of the business’s stock in a transaction on Monday, March 16th. The shares were bought at an average price of $16.00 per share, with a total value of $5,000,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jennifer B. Damico sold 2,181 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $38.35, for a total transaction of $83,641.35. Following the sale, the senior vice president now directly owns 9,647 shares in the company, valued at approximately $369,962.45. The disclosure for this sale can be found here. 0.08% of the stock is currently owned by company insiders.

Several research analysts have weighed in on PFE shares. Standpoint Research raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Mizuho reaffirmed a “buy” rating and set a $42.00 target price on shares of Pfizer in a research note on Monday, May 18th. Barclays increased their target price on shares of Pfizer from $36.00 to $37.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 29th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 target price on shares of Pfizer in a research note on Thursday, March 19th. Finally, Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 target price for the company. in a research note on Monday, May 4th. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $41.28.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.